Non-Small Cell Lung Cancer
Conditions
Brief summary
This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab
Interventions
OTHERNon-Interventional
Non-Interventional
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult male or female (≥18 years of age) patients with NSCLC * Treated with nivolumab on the Australian PAP * Initiated Nivolumab between May 2015 and August 2017 * Attending clinician agreeable to provide patient data * Local institutional ethics requirements satisfied
Exclusion criteria
* Insufficient data available Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to treatment failure (TTF) | Approximately 27 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival rate (PFSR) | Approximately 27 months | — |
| Overall survival rate (OSR) | Approximately 27 months | — |
| Incidence of AE's | Approximately 27 months | — |
| Best overall response (BOR) | Approximately 27 months | — |
| Reasons for ceasing treatment | Approximately 27 months | Any of the following: progressive disease, toxicity, patient wishes/preference, doctor decision, death |
| Incidence of patients with brain metastases | Approximately 27 months | — |
| Incidence of re-treatment | Approximately 27 months | — |
| Incidence of SAE's | Approximately 27 months | — |
Countries
Australia
Outcome results
None listed